[1]苗瑞新.造血干/祖细胞动员临床研究新进展[J].国际移植与血液净化杂志,2006,4(3):32-35.
[2]周芳,易平勇,刘晰宇,等.自体造血干细胞移植治疗多发性骨髓瘤疗效分析[J].中外医学研究, 2011,9(20):28-29.
[3]邹德慧,邱录贵.造血干细胞移植治疗多发性骨髓瘤(附视频) [J/CD].中华移植杂志:电子版,2010,4(1) :47-51.
[4]Cavo M, Rajkumar SV, Palumbo A,et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.Blood. 2011;117(23):6063-6073.
[5]黄文荣,于力.适合造血干细胞移植多发性骨髓瘤患者的治疗[J].中国实验血液学杂志,2011,19(1):249-253.
[6]Koreth J, Cutler CS, Djulbegovic B,et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant. 2007;13(2):183-196.
[7]李娟,刘俊茹,黄蓓晖,等.含硼替佐米的诱导化疗序贯自体造血干细胞移植治疗多发性骨髓瘤的疗效和安全性[J].中华内科杂志, 2012,51(4):279-283.
[8]梁蓉,陈协群,白庆成,等.PAD序贯自体造血干细胞移植治疗难治多发性骨髓瘤(附22例)[J].现代肿瘤医学, 2011,19(3):531-533.
[9]Lentzsch S, O'Sullivan A, Kennedy RC,et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.Blood. 2012;119(20):4608-4613.
[10]Eom HS, Min CK, Cho BS,et al.Retrospective comparison of bortezomib-containing regimens with vincristine- doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.Jpn J Clin Oncol. 2009;39(7):449-455.
[11]Rosiñol L, Oriol A, Teruel AI,et al.Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.Blood. 2012;120(8): 1589-1596.
[12]郭智,陈惠仁,何学鹏,等.硼替佐米联合自体造血干细胞移植治疗多发性骨髓瘤的临床分析[J].实用癌症杂志,2011, 26(1): 71-73.
[13]冯术青,李晓宇,朱梦波,等.VD方案联合自体造血干细胞移植治疗难治性不分泌型多发性骨髓瘤一例并文献复习[J]. 白血病•淋巴瘤,2011,20(2):108-110.
[14]Mikhael JR, Reeder CB, Libby III EN,et al.Results From the Phase II Dose Expansion of Cyclophosphamide, Carfilzomib, Thalidomide and Dexamethasone(CYCLONE)in Patients with Newly Diagnosed Multiple Myeloma.Blood(ASH Annual Meeting Abstracts).2012;120:Abstracts 445.
[15]Roussel M, Moreau P, Huynh A,et al. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood. 2010;115(1):32-37.
[16]宋晓晨,周芳.硼替佐米联合左旋苯丙氨酸氮芥预处理自体干细胞移植治疗多发性骨髓瘤三例[J].白血病•淋巴瘤,2012,21(4): 239-240.
[17]刘辉,常乃柏,李江涛,等.自体外周造血干细胞移植治疗21例多发性骨髓瘤的临床疗效及预后因素评价[J].临床血液学杂志,2011, 24(2):145-147.
[18]Perrone CM, Ceccolini G, Lauta M,et al. Superiority of Double over Single Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma and Prognostic Impact of Complete Response:Final Analysis of "Bologna 96" Study. Blood(ASH Annual Meeting Abstracts).2007; 110: Abstract 730.
[19]Martinez-Lopez J, Blade J, Mateos MV,et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation.Blood. 2011;118(3):529-534.
[20]Zamagni E, Di Raimondo F, Patriarca F, et al. Ten Year-Long Term Survival After up-Front Autologous Stem Cell Transplantation in Multiple Myeloma: Results From Two Prospective Clinical Trials. Blood (ASH Annual Meeting Abstracts). 2012;120: Abstract 594.
[21]Ludwig H, Spicka I, Linkesch W, et al.Double Transplantation with Melphalan (200mg/m2)Compared with Triple Transplantation with Intermediate Dose Melphalan (100mg/m2) in Patients with Multiple Myeloma.Blood(ASH Annual Meeting Abstracts). 2008;112:Abstract 3317.
[22]Kumar A, Kharfan-Dabaja MA, Glasmacher A,et al.Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.J Natl Cancer Inst. 2009;101(2): 100-106.
[23]扈江伟,江岷,胡亮钉,等.自体及减低强度的异基因外周血干细胞序贯移植治疗多发性骨髓瘤1例并文献复习[J].临床血液学杂志, 2011,24(5):557-559.
[24]Lokhorst HM, van der Holt B, Cornelissen JJ,et al. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood. 2012;119(26):6219-6225.
[25]Kumar S, Zhang MJ, Li P,et al.Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. Blood. 2011;118(7):1979-1988.
[26]Kröger N, Schwerdtfeger R, Kiehl M,et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood. 2002;100(3):755-760.
[27]Harousseau JL. How to select among available options for the treatment of multiple myeloma. Ann Oncol. 2012;23 Suppl 10: x334-338.
[28]路瑾,黄晓军.多发性骨髓瘤自体造血干细胞移植的若干技术细节进展[J].中华内科杂志,2010,49(2):171-173.
[29]赵莹,李娟,周振海,等.硼替佐米联合地塞米松方案诱导后续不同方法巩固治疗多发性骨髓瘤长期疗效观察[J].中国实用内科杂志, 2010,30(8):729-731.
[30]Reece DE,Rodriguez GP,Szwajcer D, et al. Bortezomib-Based Therapy without Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma Patients with t(4;14):A Canadian National Trial.Blood(ASH Annual Meeting Abstracts).2011;118:Abstract 3982.
[31]Cavo M, Pantani L, Petrucci MT,et al. Bortezomib- thalidomide-dexamethasone is superior to thalidomide- dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.Blood. 2012;120(1):9-19.
[32]Mateos MV, Gutiérrez NC, Martín-Ramos ML,et al. Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. Blood. 2011;118(17): 4547-4553.
[33]Mateos MV, Oriol A, Martínez-López J,et al. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.Blood. 2012;120(13):2581-2588.
[34]Ludwig H, Durie BG, McCarthy P,et al. IMWG consensus on maintenance therapy in multiple myeloma.Blood. 2012; 119(13):3003-3015.
[35]Abdelkefi A, Ladeb S, Torjman L,et al. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial.Blood. 2008;111(4):1805-1810.
[36]Morgan GJ, Gregory WM, Davies FE,et al.The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.Blood. 2012;119(1): 7-15.
[37]Kneppers E, van der Holt B, Kersten MJ,et al. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.Blood. 2011;118(9):2413-2419.
[38]Lentzsch S, O'Sullivan A, Kennedy RC,et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood. 2012;119(20):4608-4613.
[39]Benson DM Jr, Bakan CE, Zhang S,et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood. 2011;118(24):6387-6391.
[40]Sonneveld P,Asselbergs E, Zweegman S, et al. Carfilzomib Combined with Thalidomide and Dexamethasone (CTD) Is an Highly Effective Induction and Consolidation Treatment in Newly Diagnosed Patients with Multiple Myeloma (MM) Who Are Transplant Candidate.Blood(ASH Annual Meeting Abstracts). 2012;120:Abstract 333.
[41]Kumar SK,Berdeja JG, Niesvizky R, et al. A Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM).ASH Annual Meeting Abstracts. 2012; 54:Abstract 332.
[42]Dispenzieri A, Buadi F, Laumann K,et al. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.Blood. 2012;119(23):5397-5404.
[43]刘红艳,夏凌辉,郭静明,等.造血干细胞移植治疗多发性骨髓瘤的进展[J].武汉大学学报:医学版,2008,29(2):276-278.
[44]许力,林金盈,阳文捷,等.改良VAD方案治疗老年多发性骨髓瘤13例[J].中国老年学杂志,2012,32(2):365-366.
[45]Rotta M, Storer BE, Sahebi F,et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.Blood. 2009;113(14):3383-3391.
[46]李晓林,付杰,薛燕,等.自体造血干细胞移植治疗老年人恶性血液病临床观察[J].中华老年医学杂志,2010,29(3):235-236. |